Resiliency in the face of volatility

Biotech markets look to maintain their outperformance heading into 2Q26 as geopolitical uncertainty reigns as the supreme overhang.

Investors and bankers who spoke to BioCentury expect the primary drivers of the first quarter — strong follow-on and M&A markets — to continue to be the support for the sector in the near term...